同步放化疗治疗中晚期贲门癌34例临床分析  

The clinical analysis of 34 intermediate and advanced cardiac cancer with concurrent radiochemotherapy treatment

作　　者：王晋军 栗建军 杨婧娟 

机构地区：[1]山西省泽州县人民医院肿瘤科,048000

出　　处：《中国基层医药》2016年第17期2691-2694,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的：观察放疗同步化疗治疗中晚期贲门癌的疗效，探讨更有效的治疗方案。方法将34例中晚期贲门癌患者，采用同步放化疗的治疗方法，放疗采用三维适形放疗（3D-CRT），2Gy／次，每天1次，5次／周，共60 Gy／6周；化疗采用吉西他滨1000 mg／m2，静脉滴注30 min，第1、8天给药，休息1周，共2个周期。结果34例患者经治疗后复查随访，其中总有效率88．2％（30／34），1、2、3年生存率分别为70．1％（24／34）、47．0％（16／34）和26．5％（9／34），不良反应主要有消化道反应、骨髓抑制反应等，程度基本控制在1～2级，患者均可耐受。结论中晚期贲门癌经同步放化疗治疗后明显控制病情进展，症状明显改善，生存率理想，且不良反应可控制在耐受范围。Objective To observe the clinical efficacy of concurrent radiochemotherapy in the treatment of intermediate and advanced cardiac cancer.Methods Involved 34 intermediate and advanced cardiac patients,using concurrent radiochemotherapy treatment,the radio treatment with 3D -CRT method,2Gy/time,Qd,5 times per week, total 60Gy/6 week,at the same time,combined with gemcitabine treatment,1 000mg/m2 ,intravenous infusion of 30min.First day and eighth day of medication,forbidding 1 week and used 2 cycles.Results 34 patients all took part in the follow up,the total effective rate was 88.2%,the 1 -,2 -,3 -year survival rate was 70.1%（24 /34）,47.0%（16 /34）and 26.5%（9 /34）.Adverse reactions were mainly gastrointestinal reaction,bone marrow suppression,etc. Conclusion The concurrent radiochemotherapy treatment can really control the progressive disease,and receive an ideal survival rate,the adverse reactions can limit in tolerance scope.

关 键 词：胃肿瘤 放射疗法 适形 化学疗法 

分 类 号：R735.2[医药卫生—肿瘤]